The results of the present study suggest that improvement in survival of patients with NSCLC with the introduction of next-generation TKIs and anti–PD-1/PD-L1 antibodies will encourage both practitioners and patients. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.